# Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

> **NCT06299371** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 36 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** paclitaxel for injection (albumin bound)
- **DRUG:** Cisplatin or Carboplatin

## Key facts

- **NCT ID:** NCT06299371
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2026-04-15
- **Final completion:** 2029-04-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06299371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06299371, "Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06299371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*